Skip to main content
. Author manuscript; available in PMC: 2014 Jun 18.
Published in final edited form as: Curr Opin Endocrinol Diabetes Obes. 2013 Oct;20(5):434–440. doi: 10.1097/01.med.0000432531.03233.ad

Table 1.

Comparison of the therapeutic options for monocarboxylate transporter 8 deficient patients

PTU +L-T4 (n = 5) DITPA (n =4)
Doses 200–400 mg/day PTU + 100 µg/day L-T4 1~2 mg/kg/d
Effects on weight ↑ (2/2) ↑ (2/4) or remain unchanged (2/4)
Effects on TFTs nl T3, rT3, T4, TSH nl T3 and TSH, ↑ rT3 and T4 to low normal or slightly below normal range, nl T3 to T4 ratio
Effects on HPT Suppressed Not suppressed
Effects on liver ↓ SHBG (2/2) ↓ SHBG (4/4), ↑ serum cholesterol (2/4)
Effects on other peripheral tissues ↓ heart rate (1/2) ↓ heart rate (3/4), ↓ ferritin (1/4), transient ↑ CKs (4/4)
Effects on psychomotor function No significant change No significant change
Adverse effects Hypogranulocytosis (1/5) Not observed

CK, cytokines; DITPA, diiodothyropropionic acid; HPT, hypothalamic–pituitary–thyroid axis; PTU, propylthiouracil; SHBG, sex hormone binding globulin; TFTs, thyroid function tests.

↑, increase; ↓, decrease; nl, normalize.